Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,444,281
  • Shares Outstanding, K 20,342
  • Annual Sales, $ 98,430 K
  • Annual Income, $ -118,960 K
  • EBIT $ -138 M
  • EBITDA $ -134 M
  • 60-Month Beta 1.34
  • Price/Sales 17.32
  • Price/Cash Flow N/A
  • Price/Book 14.83

Options Overview Details

View History
  • Implied Volatility 83.04% (-2.99%)
  • Historical Volatility 138.32%
  • IV Percentile 8%
  • IV Rank 3.25%
  • IV High 620.58% on 04/16/25
  • IV Low 65.00% on 08/28/25
  • Expected Move (DTE 7) 5.27 (7.28%)
  • Put/Call Vol Ratio 0.66
  • Today's Volume 2,011
  • Volume Avg (30-Day) 2,483
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 42,094
  • Open Int (30-Day) 26,586
  • Expected Range 67.15 to 77.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.69
  • Number of Estimates 6
  • High Estimate -1.98
  • Low Estimate -3.68
  • Prior Year -2.25
  • Growth Rate Est. (year over year) -19.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.40 +118.88%
on 01/30/26
73.36 -0.35%
on 02/13/26
+36.53 (+99.85%)
since 01/13/26
3-Month
33.40 +118.88%
on 01/30/26
73.36 -0.35%
on 02/13/26
+19.16 (+35.51%)
since 11/13/25
52-Week
6.45 +1,033.41%
on 04/09/25
73.36 -0.35%
on 02/13/26
+59.73 (+446.50%)
since 02/13/25

Most Recent Stories

More News
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering

SAN FRANCISCO , Feb. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy,...

NKTR : 72.20 (+1.69%)
Nektar Therapeutics Announces Proposed Public Offering

SAN FRANCISCO , Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy,...

NKTR : 72.20 (+1.69%)
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg   monthly and quarterly dosing, respectively

NKTR : 72.20 (+1.69%)
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

SAN FRANCISCO , Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it...

NKTR : 72.20 (+1.69%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO , Jan. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on January 21, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 72.20 (+1.69%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised...

NKTR : 72.20 (+1.69%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised...

NKTR : 72.20 (+1.69%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised...

NKTR : 72.20 (+1.69%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised...

NKTR : 72.20 (+1.69%)
REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata

Achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28.2% in the 24 µg/kg arm versus 11.2% in placebo

NKTR : 72.20 (+1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 85.18
2nd Resistance Point 78.75
1st Resistance Point 74.87
Last Price 72.20
1st Support Level 64.56
2nd Support Level 58.13
3rd Support Level 54.25

See More

52-Week High 73.36
Last Price 72.20
Fibonacci 61.8% 47.80
Fibonacci 50% 39.90
Fibonacci 38.2% 32.01
52-Week Low 6.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar